HomeLitmys and PharmaACE announce strategic collaboration to strengthen commercial forecasting and life...

Litmys and PharmaACE announce strategic collaboration to strengthen commercial forecasting and life sciences decision-making

Litmys, a life sciences commercial strategy consulting firm specialising in commercial readiness and adoption analytics, and PharmaACE, a global life sciences consulting and analytics firm, recently announced a strategic collaboration designed to help life sciences companies make more informed development, investment and commercialisation decisions.

The collaboration brings together Litmys’ expertise in understanding and quantifying the factors that drive real-world product adoption and PharmaACE’s advanced forecasting, commercial modelling, and analytics capabilities.

By connecting these disciplines, the companies aim to help life sciences organisations develop more realistic assessments of market potential and translate those insights into stronger commercial strategies.

Traditional pharmaceutical forecasts often rely heavily on clinical profiles, market size, and assumptions about future market share. Yet commercial success ultimately depends on whether physicians prescribe, payers provide access, and patients adopt new therapies.

Understanding how these stakeholders influence one another, and how those interactions affect demand, is essential to building more reliable forecasts.

Litmys’ proprietary RAMPx (Realistic Assessment of Market Potential) methodology evaluates the drivers of real-world adoption, identifying product advantages, barriers to adoption, and stakeholder willingness to change current behaviours.

PharmaACE contributes sophisticated forecasting models, commercial analytics, and strategic consulting capabilities to help translate these insights into actionable market projections and business decisions.

What this means for life sciences companies

  • More realistic commercial forecasts: integrating stakeholder adoption insights with advanced forecasting models can help companies develop market projections grounded in how customers are likely to behave, rather than relying solely on traditional market assumptions.
  • Earlier identification of commercial risk: evaluating adoption drivers and barriers alongside forecast assumptions helps identify potential challenges before pivotal development and commercialisation decisions are finalised.
  • Better-informed investment and portfolio decisions: connecting commercial readiness assessments with financial and market modelling provides a more complete understanding of an asset’s commercial potential and the factors that could influence its value.
  • Integrated strategic and analytical support: clients can access complementary expertise in market research, adoption assessment, forecasting, and commercial analytics to support decisions from clinical development through launch and beyond.
- Advertisment -
- Advertisment -

Most Popular

Popular categories